Scott Peterson
Head of ADC Discovery Pfizer
Scott Peterson, PhD, is a Senior Vice President and the head of ADC Discovery Research at Pfizer. Previously, Scott was Senior Vice President and Head of Research at Seagen, responsible for advancing a pipeline of innovative ADC and immune oncology drugs to IND. Scott joined Seagen in 2018 after serving as the Chief Scientific Officer at Cascadian Therapeutics where he led the preclinical and translational sciences teams supporting the advancement of the selective HER2 inhibitor tucatinib (TUKYSA) to a pivotal study in HER2+ breast cancer. Prior to Cascadian, Scott served in oncology discovery research leadership roles at Zymogenetics and ICOS Corporation.
Seminars
Tuesday 13th October 2026
Panel Discussion: Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact
8:00 am
- Evaluating the landscape of ADC therapies one year on: Is the field pursuing the right amount of innovation to secure the next wave of ADCs beyond Topo1?
- Delving into payload mechanisms and non-traditional ADC design: What avenues of innovation are showing promise and what needs to be demonstrated?
- Assessing hurdles and opportunities to achieve differentiated ADC clinical profiles and patient impact in crowded oncology indications
- Peering into the crystal ball: Debating the future direction of the ADC field and pioneering future possibilities
